Published in J Clin Invest on August 01, 1974
Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol (1986) 3.64
Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest (1982) 3.49
Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest (1992) 2.47
In vivo damage of rat lungs by oxygen metabolites. J Clin Invest (1981) 2.10
In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest (1997) 2.04
Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest (1987) 1.96
Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol (1979) 1.96
Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest (1989) 1.86
Acute inflammatory pulmonary reactions induced by chemotactic factors. Am J Pathol (1979) 1.79
Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest (1996) 1.77
Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1. Am J Pathol (1993) 1.74
C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest (1979) 1.63
Suppression by superoxide dismutase of immune-complex--induced pulmonary alveolitis and dermal inflammation. Am J Pathol (1981) 1.50
In vitro and in vivo stimulation of rat neutrophils and alveolar macrophages by immune complexes. Production of O-2 and H2O2. Am J Pathol (1983) 1.46
Suppression of immune complex-induced inflammation by the chemotactic factor inactivator. J Clin Invest (1977) 1.33
Relationship of acute lung inflammatory injury to Fas/FasL system. Am J Pathol (2005) 1.33
Suppression of immune complex vasculitis in rats by prostaglandin. J Clin Invest (1979) 1.30
Acute lung injury in rat caused by immunoglobulin A immune complexes. J Clin Invest (1984) 1.29
Cationization of catalase, peroxidase, and superoxide dismutase. Effect of improved intraarticular retention on experimental arthritis in mice. J Clin Invest (1985) 1.27
NF-kappaB activation during IgG immune complex-induced lung injury: requirements for TNF-alpha and IL-1beta but not complement. Am J Pathol (1998) 1.23
Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol (1999) 1.23
Acute lung injury induced by lipopolysaccharide is independent of complement activation. J Immunol (2008) 1.22
Antileukotactic properties of tumor cells. J Clin Invest (1975) 1.19
Lipid peroxidation and acute lung injury after thermal trauma to skin. Evidence of a role for hydroxyl radical. Am J Pathol (1985) 1.18
Upregulation of phagocyte-derived catecholamines augments the acute inflammatory response. PLoS One (2009) 1.16
Hypersensitivity pneumonitis in man. Light- and electron-microscopic studies of 18 lung biopsies. Am J Pathol (1983) 1.13
Evidence for the role of platelet-activating factor in immune complex vasculitis in the rat. J Clin Invest (1989) 1.09
Attenuation of IgG immune complex-induced acute lung injury by silencing C5aR in lung epithelial cells. FASEB J (2009) 1.07
Macrophage-derived cytokines amplify immune complex-triggered O2-. responses by rat alveolar macrophages. Am J Pathol (1988) 1.04
Leukocytes in chemotactic-fragment-induced lung inflammation. Vascular emigration and alveolar surface migration. Am J Pathol (1980) 1.03
Pulmonary response of fifth component of complement-sufficient and -deficient mice to hyperoxia. J Clin Invest (1984) 1.01
Hypersensitivity pneumonitis. West J Med (1993) 1.01
Protective effects of inhibitors of nitric oxide synthase in immune complex-induced vasculitis. Br J Pharmacol (1992) 1.00
Immune complex injury of the lung. Am J Pathol (1979) 0.99
Role of C5 and recruited neutrophils in early clearance of nontypable Haemophilus influenzae from murine lungs. Infect Immun (1985) 0.99
Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement. Am J Pathol (1999) 0.98
Rous-Whipple Award Lecture. Role of complement in lung inflammatory injury. Am J Pathol (1996) 0.97
Mechanisms of enhanced lung injury during sepsis. Am J Pathol (1999) 0.97
Complement component C5 modulates the systemic tumor necrosis factor response in murine endotoxic shock. Infect Immun (1993) 0.97
Demonstration of inflammatory mediator-induced inflammation and endothelial cell damage in the anterior segment of the eye. Am J Pathol (1983) 0.96
Acute and progressive lung injury after contact with phorbol myristate acetate. Am J Pathol (1982) 0.96
Activator protein-1 activation in acute lung injury. Am J Pathol (2002) 0.95
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am J Pathol (2000) 0.95
The chemotactic response of tumor cells. A model for cancer metastasis. Am J Pathol (1981) 0.95
The effect of in situ formation of antigen-antibody complexes in the glomerulus on subsequent glomerular localization of passively administered immune complexes. Immunology (1980) 0.92
Thermal injury, intravascular hemolysis, and toxic oxygen products. J Clin Invest (1986) 0.90
Cytokine-induced neutrophil chemoattractant in a rat model of lipopolysaccharide-induced acute lung injury. Inflammation (1999) 0.90
Oleic-acid-induced lung injury in the rat. Failure of indomethacin treatment or complement depletion to ablate lung injury. Am J Pathol (1981) 0.90
Isolation and characterization of circulating immune complexes from patients with pneumococcal pneumonia. Infect Immun (1987) 0.88
Matrix metalloproteinase-3 (stromelysin-1) in acute inflammatory tissue injury. Exp Mol Pathol (2007) 0.88
Anti-KC autoantibody:KC complexes cause severe lung inflammation in mice via IgG receptors. Am J Respir Cell Mol Biol (2007) 0.86
In vitro activation of rat neutrophils and alveolar macrophages with IgA and IgG immune complexes. Implications for immune complex-induced lung injury. Am J Pathol (1987) 0.86
Regulation of inflammation by Rac2 in immune complex-mediated acute lung injury. Am J Physiol Lung Cell Mol Physiol (2009) 0.86
Regulatory dysfunction in leukotaxis. Am J Pathol (1977) 0.85
Zymosan-induced experimental hypersensitivity pneumonitis in rabbits. Am J Pathol (1980) 0.82
Immunopathology of the lung: a review. Am J Pathol (1979) 0.81
Relationship between interleukin-1 beta and platelet-activating factor in the pathogenesis of acute immune complex alveolitis in the rat. Am J Pathol (1992) 0.81
Modulation of acute immune complex-mediated tissue injury by the presence of polyionic substances. Am J Pathol (1987) 0.81
Role of interleukin-6 in immune complex induced models of vascular injury. Inflammation (2005) 0.80
Leukocyte-mediated injury to corneal endothelial cells. A model of tissue injury. Am J Pathol (1984) 0.78
Silica Triggers Inflammation and Ectopic Lymphoid Neogenesis in the Lungs in Parallel with Accelerated Onset of Systemic Autoimmunity and Glomerulonephritis in the Lupus-Prone NZBWF1 Mouse. PLoS One (2015) 0.78
Contrasting roles for tumor necrosis factor in the pathogeneses of IgA and IgG immune complex lung injury. Am J Pathol (1991) 0.77
Immunologic mechanisms of parenchymal lung injury. Environ Health Perspect (1984) 0.77
Baclofen, a GABABR agonist, ameliorates immune-complex mediated acute lung injury by modulating pro-inflammatory mediators. PLoS One (2015) 0.76
Immune complex-mediated lung injury produced by horseradish peroxidase (HRP) and anti-HRP antibodies in rats. Am J Pathol (1982) 0.76
Auto-antibody dependent activation of the autologous classical complement pathway by guinea-pig red cells treated with influenza virus or neuraminidase: in vitro and in vivo study. Immunology (1983) 0.76
Bigelovii A Protects against Lipopolysaccharide-Induced Acute Lung Injury by Blocking NF-κB and CCAAT/Enhancer-Binding Protein δ Pathways. Mediators Inflamm (2016) 0.75
Bronchial lesions of mouse model of asthma are preceded by immune complex vasculitis and induced bronchial associated lymphoid tissue (iBALT). Lab Invest (2015) 0.75
Immune complex induced arthritis in rats: role of lipid mediators on cell infiltration. Mediators Inflamm (1996) 0.75
Oxygen radicals, cytokines, adhesion molecules, and lung injury. Environ Health Perspect (1994) 0.75
The observation of immune complex formation and deposition in the eyes of living rabbits. Clin Exp Immunol (1987) 0.75
Direct leukocyte migration across pulmonary arterioles and venules into the perivascular interstitium of murine lungs during bleomycin injury and repair. Am J Pathol (2011) 0.75
Cytokine and adhesion molecule requirements for lung injury induced by anti-glomerular basement membrane antibody. Inflammation (1998) 0.75
BOUND COMPLEMENT AND IMMUNOLOGIC INJURY OF BLOOD VESSELS. J Exp Med (1965) 7.16
Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J Immunol (1969) 6.97
A ROLE OF POLYMORPHONUCLEAR LEUKOCYTES AND COMPLEMENT IN NEPHROTOXIC NEPHRITIS. J Exp Med (1965) 5.86
The role of polymorphonuclear leukocytes in the initiation and cessation of the Arthus vasculitis. J Exp Med (1959) 5.60
Experimental glomerulonephritis: immunological events and pathogenetic mechanisms. Adv Immunol (1967) 3.83
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
C3 leukotactic factors produced by a tissue protease. J Exp Med (1969) 2.19
Immunologic studies concerning the pulmonary lesions in Goodpasture's syndrome. Am J Pathol (1969) 2.11
An immunohistologic study on the occurrence of intravascular antigen-antibody precipitation and its role in anaphylaxis in the rabbit. Bull Johns Hopkins Hosp (1957) 1.94
Diseases due to immunologic reactions in the lungs (first of two parts). N Engl J Med (1972) 1.52
Experimental hemorrhagic pneumonitis produced by heterologous anti-lung antibody. J Immunol (1970) 1.42
Acute local anaphylactic inflammation of the lungs. Am J Pathol (1941) 1.38
Hypersensitivity diseases of the lungs due to fungi and organic dusts. Monogr Allergy (1969) 1.34
Immunopathologic studies of an experimental model resembling Goodpasture's syndrome. Am J Pathol (1969) 1.33
Acute experimental hypersensitivity pneumonitis in rabbits. Am Rev Respir Dis (1971) 1.07
Changes in guinea-pig lungs following the inhalation of powdered egg albumen. Pathology (1972) 1.04
High specific activity iodination of gamma-globulin with iodine-131 monochloride. ORINS Rep US At Energy Comm (1960) 0.94
Further studies on the chemotactic factor of complement and its formation in vivo. Immunology (1966) 7.59
Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol (1968) 5.77
Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science (1989) 4.99
A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med (1967) 4.94
The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase. J Exp Med (1968) 4.79
A neutrophil chemotactic factor from human C'5. J Immunol (1969) 4.46
Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol (1982) 4.38
Leukotactic factor produced by sensitized lymphocytes. Science (1969) 3.95
Mechanisms of the inhibition of chemotaxis by phosphonate esters. J Exp Med (1967) 3.87
C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J Immunol (1970) 3.75
Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun (1988) 3.63
Adhesion molecules and inflammatory injury. FASEB J (1994) 3.53
The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J Immunol (1975) 3.50
Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest (1982) 3.49
Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A (1999) 3.49
Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem (1984) 3.32
Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet (1994) 3.22
The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol (1970) 3.17
Partial biochemical characterization of the activated esterase required in the complement-dependent chemotaxis of rabbit polymorphonuclear leukocytes. J Exp Med (1967) 3.15
Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med (2001) 3.01
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
Chemotoxis of mononuclear cells. J Exp Med (1968) 2.95
Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science (1993) 2.71
The chemosuppression of chemotaxis. J Exp Med (1966) 2.62
Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin Invest (1983) 2.52
Protective effects of C5a blockade in sepsis. Nat Med (1999) 2.50
Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J Clin Invest (1991) 2.50
Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci U S A (1991) 2.49
Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest (1992) 2.47
Role of oxygen metabolites in immune complex injury of lung. J Immunol (1981) 2.39
Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem (1990) 2.37
In vitro and in vivo activity of a lymphocyte and immune complex-dependent chemotactic factor for eosinophils. J Exp Med (1971) 2.36
Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest (1971) 2.35
Neutrophil aggregation and swelling induced by chemotactic agents. J Immunol (1977) 2.26
Evidence for soluble immune complexes in the pathogenesis of the glomerulonephritis of quartan malaria. Lancet (1969) 2.22
C3 leukotactic factors produced by a tissue protease. J Exp Med (1969) 2.19
Human herpesvirus 6 in salivary glands. Lancet (1990) 2.15
Biochemical demonstration of the activatable esterase of the rabbit netrophil involved in the chemotactic response. J Immunol (1970) 2.12
In vivo damage of rat lungs by oxygen metabolites. J Clin Invest (1981) 2.10
In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest (1997) 2.04
Pulmonary endothelial cell killing by human neutrophils. Possible involvement of hydroxyl radical. Lab Invest (1985) 2.01
Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol (1979) 1.96
Role for macrophage inflammatory protein-2 in lipopolysaccharide-induced lung injury in rats. J Immunol (1996) 1.95
C5a-induced expression of P-selectin in endothelial cells. J Clin Invest (1994) 1.93
Chemotactic factor inactivator in normal human serum. J Clin Invest (1973) 1.93
Chemotactic factor influences on the aggregation, swelling, and foreign surface adhesiveness of human leukocytes. Am J Pathol (1978) 1.91
Generation of chemotactic activity in rabbit serum by plasminogen-streptokinase mixtures. J Exp Med (1967) 1.90
Leukotactic factors elaborated by virus-infected tissues. J Exp Med (1972) 1.89
Neutropenia induced by systemic infusion of chemotactic factors. J Immunol (1977) 1.89
Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies. Neurology (1989) 1.88
Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med (1974) 1.88
Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest (1989) 1.86
Acute inflammatory pulmonary reactions induced by chemotactic factors. Am J Pathol (1979) 1.79
Impaired leucotactic responsiveness in a child with recurrent infections. Lancet (1969) 1.78
Selective neutrophil desensitization to chemotactic factors. J Cell Biol (1979) 1.77
Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest (1996) 1.77
Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1. Am J Pathol (1993) 1.74
Leukotactic factors in health and disease. Am J Pathol (1971) 1.71
Impaired neutrophil chemotaxis in patients with juvenile and rapidly progressing periodontitis. J Periodontal Res (1979) 1.70
Inhibition of lung inflammatory reactions in rats by an anti-human IL-8 antibody. J Immunol (1993) 1.68
Neutrophil chemotactic factors and related clinical disorders. Arthritis Rheum (1970) 1.68
Molecular cloning and characterization of DEFCAP-L and -S, two isoforms of a novel member of the mammalian Ced-4 family of apoptosis proteins. J Biol Chem (2000) 1.66
Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest (1993) 1.64
Lung and dermal vascular injury produced by preformed immune complexes. Am Rev Respir Dis (1978) 1.64
Pathogenesis of the granulomatous lung diseases. Am Rev Respir Dis (1984) 1.64
C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest (1979) 1.63
Isolation from human serum of an inactivator of bacterial lipopolysaccharide. Am J Pathol (1977) 1.58
Influence of inhibitors of cellular function on chemotactic factor-induced neutrophil aggregation. J Immunol (1977) 1.57
Phlebotomy overdraw in the neonatal intensive care nursery. Pediatrics (2000) 1.57
Two distinct chemotactic factor inactivators in human serum. J Immunol (1975) 1.55
Inhibition of in vivo and in vitro neutrophil responses to chemotactic factors by a competitive antagonist. J Immunol (1978) 1.55
Endothelial cell killing by neutrophils. Synergistic interaction of oxygen products and proteases. Am J Pathol (1989) 1.55
Chemotaxis of human eosinophils. Am J Pathol (1969) 1.54
Role of C5a in multiorgan failure during sepsis. J Immunol (2001) 1.53
The effect of inhaled nitric oxide therapy on bleeding time and platelet aggregation in neonates. J Pediatr (1998) 1.53
Chemotaxis of rat lymphocytes. J Immunol (1977) 1.53
Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol (1995) 1.53
Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. J Immunol (1995) 1.52
Biologic role of complement products. Complement-derived leukotactic activity extractable from lesions of immunologic vasculitis. J Immunol (1972) 1.51
Leukotactic dystunction in sarcoidosis. Ann Intern Med (1976) 1.50
Suppression by superoxide dismutase of immune-complex--induced pulmonary alveolitis and dermal inflammation. Am J Pathol (1981) 1.50
Mediator-induced activation of xanthine oxidase in endothelial cells. FASEB J (1989) 1.49
Requirements for leukocyte adhesion molecules in nephrotoxic nephritis. J Clin Invest (1993) 1.49
Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest (2000) 1.49
Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol (1997) 1.49
Chemoattractants of leukocytes, with special reference to lymphocytes. Fed Proc (1972) 1.48
Biochemical quantitation of the chemotactic factor inactivator activity in human serum. J Lab Clin Med (1979) 1.46
In vitro and in vivo stimulation of rat neutrophils and alveolar macrophages by immune complexes. Production of O-2 and H2O2. Am J Pathol (1983) 1.46
Congenital 21-hydroxylase deficiency as a new deletion mutation. Detection in a proband during subsequent prenatal diagnosis by HLA typing and DNA analysis. Hum Immunol (1992) 1.45